Senseonics Expands Distribution Agreement with Roche
Roche Diabetes Care to Distribute the Eversense® CGM System across
Europe, the Middle East and Africa
GERMANTOWN, Md.--(BUSINESS WIRE)--
Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company
focused on the development and commercialization of a long-term,
implantable continuous glucose monitoring (CGM) system for people with
diabetes, today announced it has expanded its exclusive distribution
agreement with Roche to include all of Europe, the Middle East and
Africa (EMEA), excluding Scandinavia, Finland and Israel. In May of this
year, Senseonics signed an exclusive distribution with Roche for the
commercialization of Senseonics’ Eversense® Continuous Glucose
Monitoring System in Germany, Italy and the Netherlands.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20161202005186/en/
Under the terms of the expanded agreement, Senseonics has granted Roche
exclusive rights to promote, market, and sell the Eversense product line
to diabetes clinics and patients in the covered territories.
“The partnership we formed with Roche earlier this year is off to a
promising start. The early success and experience that each of our teams
are gaining drove the mutual decision to expand our relationship. We are
excited to add these additional countries and look forward to growing
the presence of Eversense through this partnership,” said Tim Goodnow,
CEO and President of Senseonics.
Senseonics will retain responsibility for product development,
regulatory approval, quality management, and manufacturing, while Roche
will be responsible for sales, marketing, customer support and
distribution activities in the covered territories.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of glucose monitoring products
designed to help people with diabetes confidently live their lives with
ease. Senseonics’ first generation CGM system, Eversense®, includes a
small sensor, smart transmitter and mobile application. Based on
fluorescence sensing technology, the sensor is designed to be inserted
subcutaneously and communicate with the smart transmitter to wirelessly
transmit glucose levels to a mobile device. After insertion, the sensor
is designed to continually and accurately measure glucose levels. For
more information on Senseonics, please visit www.senseonics.com.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on
advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated
medicines in oncology, immunology, infectious diseases, ophthalmology
and diseases of the central nervous system. Roche is also the world
leader in in vitro diagnostics and tissue-based cancer
diagnostics, and a frontrunner in diabetes management. The combined
strengths of pharmaceuticals and diagnostics under one roof have made
Roche the leader in personalised healthcare – a strategy that aims to
fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent,
diagnose and treat diseases and make a sustainable contribution to
society. Twenty-nine medicines developed by Roche are included in the
World Health Organization Model Lists of Essential Medicines, among them
life-saving antibiotics, antimalarials and cancer medicines. Roche has
been recognised as the Group Leader in sustainability within the
Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a
row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over
100 countries and in 2015 employed more than 91,700 people worldwide. In
2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1
billion. Genentech, in the United States, is a wholly owned member of
the Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan. For more information, please visit www.roche.com
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose
monitoring systems and a global leader for diabetes management systems
and services. For more than 40 years, the Accu-Chek brand has been
dedicated to enabling people with diabetes to live life as normally and
actively as possible as well as to empowering healthcare professionals
to manage their patients’ condition in an optimal way. Today, the
Accu-Chek portfolio offers people with diabetes and healthcare
professionals innovative products and impactful solutions for
convenient, efficient and effective diabetes management, spanning from
blood glucose monitoring through information management to insulin
delivery. The Accu-Chek brand encompasses blood glucose meters, insulin
delivery systems, lancing devices, data management systems and education
programs – contributing to an improved medical outcome.
For more information please visit www.accu-chek.com
All trademarks used or mentioned in this release are protected by law.
Forward Looking Statements
Certain statements contained in this press release, other than
statements of fact that are independently verifiable at the date hereof,
may constitute “forward-looking statements.” These forward-looking
statements reflect Senseonics’ current views about its plans,
intentions, expectations, strategies and prospects, including statements
concerning the marketing and commercialization of Eversense in Europe,
the Middle East and Africa, which are based on the information currently
available to Senseonics and on assumptions Senseonics has made. Although
Senseonics believes that its plans, intentions, expectations, strategies
and prospects as reflected in or suggested by those forward-looking
statements are reasonable, Senseonics can give no assurance that the
plans, intentions, expectations or strategies will be attained or
achieved. Furthermore, actual results may differ materially from those
described in the forward-looking statements and will be affected by a
variety of risks and factors that are beyond Senseonics’ control. Other
risks and uncertainties are more fully described in the section entitled
“Risk Factors” in Senseonics’ Annual Report on Form 10-K filed with the
Securities and Exchange Commission (SEC) on February 19, 2016, its
Quarterly Report on Form 10-Q filed with the SEC on November 3, 2016 and
its other SEC filings. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. The statements made in this press
release speak only as of the date stated herein, and subsequent events
and developments may cause Senseonics’ expectations and beliefs to
change. Unless otherwise required by applicable securities laws,
Senseonics does not intend, nor do it undertake any obligation, to
update or revise any forward-looking statements contained in this news
release to reflect subsequent information, events, results or
circumstances or otherwise. While Senseonics may elect to update these
forward-looking statements publicly at some point in the future,
Senseonics specifically disclaims any obligation to do so, whether as a
result of new information, future events or otherwise, except as
required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161202005186/en/
Senseonics Holdings, Inc.
R. Don Elsey, 301-556-1602
Chief
Financial Officer
[email protected]
Source: Senseonics Holdings, Inc.